Community Outreach and Engagement (COE)

社区外展和参与：摘要 亚利桑那大学癌症中心（UACC）的农村和城市集水区达到美国-墨西哥 与亚利桑那州南部的五个县（科奇斯、皮马、皮纳尔、圣克鲁斯和尤马）接壤，包括 超过180万居民，其中39%是西班牙裔，2.5%是美洲印第安人/阿拉斯加原住民（AI/AN）- 高癌症负担和差异的人群。社区外展办公室的目标和 承诺（COE）是作为一个关键的桥梁连接UACC的不同集水区人口， 科学界加强参与研究，临床试验和临床护理，减少癌症 负担在Jennifer Hatcher，RN，MPH，PhD的领导下，在UACC正式成立3年，COE是 由一个代表亚利桑那州不同人口的多元文化、双语成员组成的团队推动。该团队正在 由组成社区的各种外部利益相关者和社区成员提供建议 咨询委员会（CAB）和内部利益相关者组成了内部咨询委员会（IAC）。的 COE的具体目标是：（1）确定和监测癌症负担和癌症相关需求， UACC集水区;（2）促进有影响力的研究和临床试验，重点关注UACC优先癌症， 与战略计划保持一致;（3）领导社区外联活动，使机构和社区协同增效 努力减少流域癌症健康差距;（4）促进政策建议，重点是 减少亚利桑那州及其他地区的癌症差异和癌症负担。特遣队所属装备促进UACC努力， 有效解决流域人口的特定癌症负担，包括优先癌症（肺癌， 乳腺、胃肠道[GI]、泌尿生殖系统[GU]和黑色素瘤）;西班牙裔美国人的癌症筛查率较低 和人工智能/人工神经网络;以及在获得治疗方面的挑战，包括在农村和边境地区。差距 通过全流域合作伙伴关系的结合来解决;有针对性的社区教育和 在积极的CAB指导下开展外联活动;支持有影响力的、前沿的、创新的研究。努力 使用综合逻辑模型进行评估，该模型展示了COE的影响和相互关联性 整个机构和社区的活动。COE工作包括完成一个粒度 集水区的特征，以支持高优先级癌症的选择和建立一个 与亚利桑那州卫生服务部正式合作。努力的影响包括增加 关于流域相关癌症的知识，重点关注流域相关癌症的赠款提交 和人口，流域相关的规划和推广，以及流域居民与 研究和临床服务。未来的方向包括与UACC的人口健康AD合作 开展人口健康评估，进一步确定癌症负担/优先事项， 建立一个文化上敏感的工具包，以加强对任职人数不足的人员的征聘 临床试验中的少数民族。

COMMUNITY OUTREACH AND ENGAGEMENT: ABSTRACT The University of Arizona Cancer Center’s (UACC) rural and urban Catchment Area reaches the US-Mexico border and spans five Southern Arizona counties (Cochise, Pima, Pinal, Santa Cruz, and Yuma) comprising more than 1.8M residents, of which 39% are Hispanic and 2.5% American Indian/Alaskan Native (AI/AN)— populations with high cancer burden and disparities. The goal of the Office of Community Outreach and Engagement (COE) is to serve as a critical bridge linking the UACC’s diverse Catchment population to the scientific community to enhance participation in research, clinical trials, and clinical care and decrease cancer burden. Formalized at UACC for 3 years under the leadership of Jennifer Hatcher, RN, MPH, PhD, COE is driven by a team of multicultural, bilingual members representative of Arizona’s diverse population. The team is advised by a diverse set of external stakeholders and community members who comprise the Community Advisory Board (CAB) and internal stakeholders who comprise an Internal Advisory Committee (IAC). The Specific Aims of COE are to: (1) Characterize and monitor cancer burden and cancer-related needs within the UACC Catchment Area; (2) Facilitate impactful research and clinical trials focusing on UACC priority cancers in alignment with the Strategic Plan; (3) Lead community outreach that synergizes institutional and community efforts to reduce Catchment cancer health disparities; and (4) Promote policy recommendations focusing on reduction of cancer disparities and cancer burden in Arizona and beyond. COE facilitates UACC efforts to effectively address the specific cancer burden of the Catchment population, including priority cancers (lung, breast, gastrointestinal [GI], genitourinary [GU], and melanoma); low cancer screening rates among Hispanics and AI/ANs; and challenges to treatment access, including in rural and frontier areas. Disparities are addressed through a combination of Catchment-wide partnerships; targeted community-based education and outreach guided by an active CAB; and support for impactful, cutting-edge, innovative research. Efforts are evaluated using a comprehensive logic model that demonstrates the impact and interconnectedness of COE activities across the institution and community. COE efforts have included completion of a granular characterization of the Catchment Area to support the selection of high priority cancers and establishment of a formal partnership with the Arizona Department of Health Services. Impact of efforts includes increased knowledge regarding Catchment-relevant cancers, grant submissions focused on Catchment-relevant cancers and populations, Catchment-relevant programming and outreach, and connections for Catchment residents to research and clinical services. Future directions include partnering with UACC’s AD of Population Health Sciences to conduct a population health assessment further characterizing the cancer burden/priorities of the Catchment Area and building a culturally responsive tool kit to enhance recruitment of underrepresented minorities in clinical trials.